Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 6 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
J Hematol Oncol. 2023 Jul 8;16(1):73. doi: 10.1186/s13045-023-01476-8.
J Hematol Oncol. 2023.
PMID: 37422688
Free PMC article.
Clinical Trial.
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
Carter BZ, Mak PY, Muftuoglu M, Tao W, Ke B, Pei J, Bedoy AD, Ostermann LB, Nishida Y, Isgandarova S, Sobieski M, Nguyen N, Powell RT, Martinez-Moczygemba M, Stephan C, Basyal M, Pemmaraju N, Boettcher S, Ebert BL, Shpall EJ, Wallner B, Morgan RA, Karras GI, Moll UM, Andreeff M.
Carter BZ, et al. Among authors: basyal m.
Blood. 2023 Sep 21;142(12):1056-1070. doi: 10.1182/blood.2022019047.
Blood. 2023.
PMID: 37339579
Item in Clipboard
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.
Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, Daver N, Kantarjian HM, Andreeff M, DiNardo CD.
Senapati J, et al. Among authors: basyal m.
Blood Cancer J. 2023 Jun 29;13(1):101. doi: 10.1038/s41408-023-00871-1.
Blood Cancer J. 2023.
PMID: 37386016
Free PMC article.
Clinical Trial.
Item in Clipboard
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.
Jia Y, Zhang W, Basyal M, Chang KH, Ostermann L, Burks JK, Ly C, Mu-Mosley H, Zhang Q, Han X, Fogler WE, Magnani JL, Lesegretain A, Zal AA, Zal T, Andreeff M.
Jia Y, et al. Among authors: basyal m.
Leukemia. 2023 Jun;37(6):1379-1383. doi: 10.1038/s41375-023-01897-x. Epub 2023 Apr 21.
Leukemia. 2023.
PMID: 37085610
Free PMC article.
No abstract available.
Item in Clipboard
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
Zhang W, Yu G, Zhang H, Basyal M, Ly C, Yuan B, Ruvolo V, Piya S, Bhattacharya S, Zhang Q, Borthakur G, Battula V, Konopleva M, Rice WG, Andreeff M.
Zhang W, et al. Among authors: basyal m.
Haematologica. 2023 Jun 1;108(6):1500-1514. doi: 10.3324/haematol.2022.280884.
Haematologica. 2023.
PMID: 36226489
Free PMC article.
Item in Clipboard
In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals.
Li L, Muftuoglu M, Liang S, Basyal M, Lv J, Akdogan ME, Chen K, Andreeff M, Flowers CR, Parmar S.
Li L, et al. Among authors: basyal m.
JCI Insight. 2022 Apr 8;7(7):e156559. doi: 10.1172/jci.insight.156559.
JCI Insight. 2022.
PMID: 35230977
Free PMC article.
Item in Clipboard
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and Aurora kinases.
Yu G, Zhang W, Zhang H, Ly C, Basyal M, Rice WG, Andreeff M.
Yu G, et al. Among authors: basyal m.
Res Sq [Preprint]. 2023 Feb 22:rs.3.rs-2570204. doi: 10.21203/rs.3.rs-2570204/v1.
Res Sq. 2023.
PMID: 36865133
Free PMC article.
Preprint.
Item in Clipboard
Cite
Cite